Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of “Hold” from Brokerages

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have received a consensus rating of “Hold” from the eight research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $20.40.

KROS has been the subject of a number of recent research reports. Wells Fargo & Company dropped their price objective on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, March 5th. Wall Street Zen cut shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings cut shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th.

Keros Therapeutics Stock Performance

KROS opened at $10.99 on Friday. The stock has a market capitalization of $217.49 million, a price-to-earnings ratio of -3.65 and a beta of 0.94. The company has a fifty day moving average of $10.99 and a 200 day moving average of $14.40. Keros Therapeutics has a fifty-two week low of $9.69 and a fifty-two week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%.The business had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $1.93 million. On average, equities research analysts forecast that Keros Therapeutics will post -5.19 earnings per share for the current year.

Insiders Place Their Bets

In other Keros Therapeutics news, Director Julius Knowles sold 2,625 shares of Keros Therapeutics stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the transaction, the director directly owned 10,958 shares of the company’s stock, valued at $117,579.34. This trade represents a 19.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of Keros Therapeutics stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.72, for a total transaction of $28,140.00. Following the completion of the transaction, the director directly owned 9,767 shares of the company’s stock, valued at $104,702.24. The trade was a 21.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,425 shares of company stock valued at $89,995 in the last three months. Corporate insiders own 20.60% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Several institutional investors have recently made changes to their positions in the company. ADAR1 Capital Management LLC lifted its holdings in shares of Keros Therapeutics by 416.2% in the 1st quarter. ADAR1 Capital Management LLC now owns 97,318 shares of the company’s stock worth $1,074,000 after acquiring an additional 78,467 shares during the last quarter. Empowered Funds LLC lifted its holdings in shares of Keros Therapeutics by 142.2% in the 1st quarter. Empowered Funds LLC now owns 145,517 shares of the company’s stock worth $1,607,000 after acquiring an additional 85,439 shares during the last quarter. Quantinno Capital Management LP lifted its holdings in shares of Keros Therapeutics by 12.5% in the 1st quarter. Quantinno Capital Management LP now owns 23,759 shares of the company’s stock worth $262,000 after acquiring an additional 2,639 shares during the last quarter. Lazard Asset Management LLC bought a new stake in shares of Keros Therapeutics in the 1st quarter worth about $129,000. Finally, Globeflex Capital L P bought a new stake in shares of Keros Therapeutics in the 1st quarter worth about $418,000. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.